GSK2251052 in the Treatment of Complicated Intra-abdominal Infections
Status:
Terminated
Trial end date:
2012-03-05
Target enrollment:
Participant gender:
Summary
This study is being conducted to evaluate the safety, efficacy and
pharmacokinetics/pharmacodynamics of GSK2251052 in subjects with complicated intra abdominal
infections. GSK2251052 will be compared to meropenem, an IV therapy that is approved for use
in the treatment of subjects with cIAI. GSK2251052 has a spectrum of microbiological activity
that includes pathogens responsible for cIAI.